NASDAQ:BCAB BioAtla (BCAB) Stock Forecast, Price & News $3.47 +0.15 (+4.52%) (As of 06/2/2023 ET) Add Compare Share Share Today's Range$3.25▼$3.5050-Day Range$2.35▼$3.8752-Week Range$2.23▼$12.15Volume402,031 shsAverage Volume299,047 shsMarket Capitalization$165.41 millionP/E RatioN/ADividend YieldN/APrice Target$15.67 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media BioAtla MarketRank™ ForecastAnalyst RatingModerate Buy2.83 Rating ScoreUpside/Downside351.5% Upside$15.67 Price TargetShort InterestHealthy7.53% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.22Based on 2 Articles This WeekInsider TradingAcquiring Shares$148,776 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($2.48) to ($2.15) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.33 out of 5 starsMedical Sector229th out of 983 stocksBiological Products, Except Diagnostic Industry28th out of 164 stocks 3.4 Analyst's Opinion Consensus RatingBioAtla has received a consensus rating of Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $15.67, BioAtla has a forecasted upside of 351.5% from its current price of $3.47.Amount of Analyst CoverageBioAtla has only been the subject of 4 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted7.53% of the outstanding shares of BioAtla have been sold short.Short Interest Ratio / Days to CoverBioAtla has a short interest ratio ("days to cover") of 7.2.Change versus previous monthShort interest in BioAtla has recently decreased by 5.03%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldBioAtla does not currently pay a dividend.Dividend GrowthBioAtla does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BCAB. Previous Next 2.3 News and Social Media Coverage News SentimentBioAtla has a news sentiment score of 1.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for BioAtla this week, compared to 2 articles on an average week.Search InterestOnly 3 people have searched for BCAB on MarketBeat in the last 30 days. This is a decrease of -86% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added BioAtla to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, BioAtla insiders have bought more of their company's stock than they have sold. Specifically, they have bought $148,776.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders14.80% of the stock of BioAtla is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions66.15% of the stock of BioAtla is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for BioAtla are expected to grow in the coming year, from ($2.48) to ($2.15) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BioAtla is -1.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BioAtla is -1.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBioAtla has a P/B Ratio of 1.06. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About BioAtla (NASDAQ:BCAB) StockBioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and ovarian cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California.Read More Receive BCAB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioAtla and its competitors with MarketBeat's FREE daily newsletter. Email Address BCAB Stock News HeadlinesJune 1, 2023 | americanbankingnews.comShort Interest in BioAtla, Inc. (NASDAQ:BCAB) Declines By 5.0%May 31, 2023 | finance.yahoo.comBioAtla to Participate in the Jefferies Healthcare ConferenceJune 4, 2023 | Vantage Point (Ad)Instantly Find Hidden Trade OpportunitiesThere’s a tool that scans and picks the best stocks…how you approach the trades is up to you. But when you’re forecasting 1 – 3 days in advance, it’s not really a guessing game. Stop guessing and start predicting to add consistency to your trades… no matter what happens in the market. May 26, 2023 | americanbankingnews.comBioAtla, Inc. (NASDAQ:BCAB) Receives $15.67 Average PT from AnalystsMay 19, 2023 | americanbankingnews.comQ2 2023 Earnings Forecast for BioAtla, Inc. (NASDAQ:BCAB) Issued By HC WainwrightMay 16, 2023 | msn.comJMP Securities Reiterates BioAtla (BCAB) Outperform RecommendationMay 16, 2023 | americanbankingnews.comBioAtla, Inc. (NASDAQ:BCAB) Expected to Post Q1 2024 Earnings of ($0.61) Per ShareMay 15, 2023 | markets.businessinsider.comWhere BioAtla Stands With AnalystsJune 4, 2023 | Vantage Point (Ad)Instantly Find Hidden Trade OpportunitiesThere’s a tool that scans and picks the best stocks…how you approach the trades is up to you. But when you’re forecasting 1 – 3 days in advance, it’s not really a guessing game. Stop guessing and start predicting to add consistency to your trades… no matter what happens in the market. May 15, 2023 | msn.comHC Wainwright & Co. Reiterates BioAtla (BCAB) Buy RecommendationMay 15, 2023 | markets.businessinsider.comH.C. Wainwright Keeps Their Buy Rating on BioAtla (BCAB)May 15, 2023 | markets.businessinsider.comBioAtla (BCAB) Receives a Buy from JMP SecuritiesMay 13, 2023 | msn.comEF Hutton Reiterates BioAtla (BCAB) Buy RecommendationMay 12, 2023 | markets.businessinsider.comBioAtla (BCAB) Receives a Buy from BTIGMay 11, 2023 | finance.yahoo.comBioAtla Reports First Quarter 2023 Financial Results and Highlights Recent ProgressMay 11, 2023 | investing.comBioatla (BCAB) Earnings Dates & ReportsMay 8, 2023 | finance.yahoo.comBioAtla to Participate in the JMP Securities Life Sciences ConferenceMay 4, 2023 | finance.yahoo.comBioAtla to Announce First Quarter 2023 Financial Results and Provide Business Highlights on May 11, 2023May 1, 2023 | americanbankingnews.comBioAtla, Inc. (NASDAQ:BCAB) Receives $15.67 Average Price Target from AnalystsApril 29, 2023 | finance.yahoo.comWe Think BioAtla (NASDAQ:BCAB) Needs To Drive Business Growth CarefullyApril 19, 2023 | msn.comEF Hutton Maintains BioAtla (BCAB) Buy RecommendationApril 19, 2023 | americanbankingnews.comBioAtla (NASDAQ:BCAB) Given Buy Rating at EF Hutton Acquisition Co. IApril 8, 2023 | americanbankingnews.comBioAtla, Inc. (NASDAQ:BCAB) Receives $15.67 Consensus Target Price from AnalystsApril 3, 2023 | americanbankingnews.comBioAtla (NASDAQ:BCAB) Price Target Lowered to $19.00 at JPMorgan Chase & Co.April 1, 2023 | americanbankingnews.comBioAtla, Inc. (NASDAQ:BCAB) CEO Purchases $100,776.00 in StockMarch 30, 2023 | americanbankingnews.comBioAtla, Inc. (NASDAQ:BCAB) Insider Christian Vasquez Acquires 20,000 SharesMarch 30, 2023 | americanbankingnews.comBioAtla (NASDAQ:BCAB) Price Target Cut to $13.00See More Headlines BCAB Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BCAB Company Calendar Last Earnings3/23/2023Today6/04/2023Next Earnings (Estimated)8/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BCAB CUSIPN/A CIK1826892 Webwww.bioatla.com Phone858-558-0708FaxN/AEmployees56Year FoundedN/APrice Target and Rating Average Stock Price Forecast$15.67 High Stock Price Forecast$25.00 Low Stock Price Forecast$8.00 Forecasted Upside/Downside+351.5%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($2.67) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-106,480,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-68.09% Return on Assets-52.68% Debt Debt-to-Equity RatioN/A Current Ratio7.61 Quick Ratio7.61 Sales & Book Value Annual Sales$250,000.00 Price / Sales661.66 Cash FlowN/A Price / Cash FlowN/A Book Value$3.28 per share Price / Book1.06Miscellaneous Outstanding Shares47,670,000Free Float40,613,000Market Cap$165.41 million OptionableNot Optionable Beta0.27 Key ExecutivesDr. Jay M. Short Ph.D. (Age 65)Co-Founder, CEO & Chairman Comp: $1.02MMr. Scott Andrew Smith (Age 61)Pres & Director Comp: $798.89kMr. Richard A. Waldron (Age 69)Chief Financial Officer Comp: $593.51kDr. Eric L. Sievers M.D. (Age 59)Chief Medical Officer Comp: $552.62kMr. Christian Vasquez (Age 48)VP of Fin., Corp. Controller & Sec. Comp: $345.88kMr. Philippe Martin (Age 47)Chief Clinical Devel. & Operations Lisa M. PeltonAccounting Mang.Ms. Susie MelodySr. VP of HRDr. Cathy Chang Ph.D.Sr. VP of R&DMs. Monica SullivanSr. VP of Intellectual Property & ContractsMore ExecutivesKey CompetitorsZura BioNASDAQ:ZURAINmune BioNASDAQ:INMBSorrento TherapeuticsNASDAQ:SRNEGamida CellNASDAQ:GMDAAtara BiotherapeuticsNASDAQ:ATRAView All CompetitorsInsiders & InstitutionsPrelude Capital Management LLCSold 3,327 shares on 6/1/2023Ownership: 0.027%Toroso Investments LLCBought 54,080 shares on 5/23/2023Ownership: 0.186%JPMorgan Chase & Co.Sold 155,719 shares on 5/18/2023Ownership: 0.021%State Street CorpBought 13,600 shares on 5/16/2023Ownership: 0.280%Squarepoint Ops LLCBought 4,243 shares on 5/16/2023Ownership: 0.040%View All Insider TransactionsView All Institutional Transactions BCAB Stock - Frequently Asked Questions Should I buy or sell BioAtla stock right now? 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BioAtla in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BCAB shares. View BCAB analyst ratings or view top-rated stocks. What is BioAtla's stock price forecast for 2023? 6 brokerages have issued twelve-month price objectives for BioAtla's stock. Their BCAB share price forecasts range from $8.00 to $25.00. On average, they anticipate the company's stock price to reach $15.67 in the next twelve months. This suggests a possible upside of 351.5% from the stock's current price. View analysts price targets for BCAB or view top-rated stocks among Wall Street analysts. How have BCAB shares performed in 2023? BioAtla's stock was trading at $8.25 at the beginning of the year. Since then, BCAB shares have decreased by 57.9% and is now trading at $3.47. View the best growth stocks for 2023 here. Are investors shorting BioAtla? BioAtla saw a decrease in short interest during the month of May. As of May 15th, there was short interest totaling 3,590,000 shares, a decrease of 5.0% from the April 30th total of 3,780,000 shares. Based on an average daily trading volume, of 499,900 shares, the days-to-cover ratio is currently 7.2 days. View BioAtla's Short Interest. When is BioAtla's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023. View our BCAB earnings forecast. How were BioAtla's earnings last quarter? BioAtla, Inc. (NASDAQ:BCAB) issued its earnings results on Thursday, March, 23rd. The company reported ($0.63) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.74) by $0.11. What ETFs hold BioAtla's stock? ETFs with the largest weight of BioAtla (NASDAQ:BCAB) stock in their portfolio include Formidable ETF (FORH).ALPS Medical Breakthroughs ETF (SBIO). When did BioAtla IPO? (BCAB) raised $150 million in an IPO on Wednesday, December 16th 2020. The company issued 9,400,000 shares at $15.00-$17.00 per share. J.P. Morgan, Jefferies, Credit Suisse and BTIG acted as the underwriters for the IPO. What is BioAtla's stock symbol? BioAtla trades on the NASDAQ under the ticker symbol "BCAB." Who are BioAtla's major shareholders? BioAtla's stock is owned by a number of retail and institutional investors. Top institutional investors include Candriam S.C.A. (3.29%), Wasatch Advisors LP (2.66%), BlackRock Inc. (2.07%), Deutsche Bank AG (1.45%), Vontobel Holding Ltd. (1.16%) and Sectoral Asset Management Inc. (1.14%). Insiders that own company stock include Christian Vasquez, Cormorant Asset Management, Lp, Eric Sievers, Guy Levy, Jay M Phd Short, Lawrence Steinman, Richard A Waldron, Scott Andrew Smith and Sylvia Mcbrinn. View institutional ownership trends. How do I buy shares of BioAtla? Shares of BCAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is BioAtla's stock price today? One share of BCAB stock can currently be purchased for approximately $3.47. How much money does BioAtla make? BioAtla (NASDAQ:BCAB) has a market capitalization of $165.41 million and generates $250,000.00 in revenue each year. The company earns $-106,480,000.00 in net income (profit) each year or ($2.67) on an earnings per share basis. How can I contact BioAtla? The official website for the company is www.bioatla.com. The company can be reached via phone at 858-558-0708 or via email at investors@bioatla.com. This page (NASDAQ:BCAB) was last updated on 6/4/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioAtla, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.